THERAPY DOSSIER · th-24ca60ce87e3

Sesquiterpenoids from the root of Panax Ginseng (SPG)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29573620 ↗2018Reported benefit

Sesquiterpenoids from the root of Panax Ginseng protect CCl-induced acute liver injury by anti-inflammatory and anti-oxidative capabilities in mice.

MouseChemical/toxinICRMaleIntragastric2.5 and 10 mg/kg, dissolved in soybean oilSPG given for 7 days before CCl4 injection; CCl4 injected 1 hour after the end…

Model: Carbon tetrachloride (CCl4)-induced acute liver injury

SPG treatment at 2.5 and 10 mg/kg significantly reduced CCl4-induced elevations in serum AST and ALT, preserved normal liver architecture with no necrosis, restored antioxidant enzyme activities and reduced MDA, decreased proinflammatory cytokines, and reduced hepatic NF-kB p65, COX-2, MAPK p38, ER…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…